Carlos Menendez, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1346268513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 527 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,159 and has fallen 70.0% since, to $648 in 2025.
Across 527 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$2K
- Novo Nordisk$2K
- Lilly USA, LLC$953
- Abbott$842
- IBSA Pharma Inc.$662
- Sanofi-aventis U.S. LLC$654
- plus $5K from 45 others
Across 81 payments — averaging $2052.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$121K
- Regeneron$23K
- Ionis Pharmaceuticals, Inc.$12K
- Janssen Research & Development, LLC$10K
- Novo Nordisk AS$20
What the payments were for
- Consulting fees$7227%
- Food & beverage$10,29593%
- Education$270%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tirosint$500
- Tirosint-SOL$500
- Ozempic$239
- Omnipod$130
- TLANDO$125
- Kerendia$122
- CeQur Simplicity$107
How this compares
$11,103 in reported general payments places this provider in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 216 | $292,679 |
| RybelsusSemaglutide | 95 | $126,455 |
| MounjaroTirzepatide | 83 | $109,978 |
| TrulicityDulaglutide | 88 | $89,668 |
| SynthroidLevothyroxine Sodium | 936 | $79,776 |
| TymlosAbaloparatide | 15 | $63,544 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 51 | $58,880 |
| KerendiaFinerenone | 50 | $57,576 |
| AfrezzaInsulin Regular, Human | 22 | $47,492 |
| Repatha SureclickEvolocumab | 52 | $45,669 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $42,289 |
| TradjentaLinagliptin | 29 | $28,132 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $27,884 |
| VascepaIcosapent Ethyl | 39 | $24,782 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $20,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,507 | $426,404340 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $953 | $206,458204 claims |
| MerckJanumet Xr, Janumet, Januvia | $63 | $115,379112 claims |
| AbbVieSynthroid, Armour Thyroid | $574 | $81,124959 claims |
| Radius Health, Inc.Tymlos | $196 | $63,54415 claims |
| BayerKerendia | $535 | $57,57650 claims |
| Mannkind CorporationAfrezza | $1,514 | $47,49222 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $654 | $14,16918 claims |
| Esperion Therapeutics, Inc.Nexlizet | $97 | $12,36320 claims |
| IBSA Pharma Inc.Tirosint | $662 | $2,68812 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $21 | $1,69419 claims |
| Amneal Pharmaceuticals LLCUnithroid | $20 | $1,08426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Ralph DefronzoSan Antonio$880K
- Firas AkhrassSan Antonio$801K
- Carolina Solis-HerreraSan Antonio$600K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- Shahid AzizSan Antonio$173K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.